Skip to main content

Finance & Corporate

Thu, 10/12/2017 - 17:00
  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

Tue, 07/18/2017 - 17:00
  • With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

 

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter